glp 1 fda compounding GLP-1 is facing increased scrutiny, and the path forward is far from clear., ㅤ, Recent messaging has raised questions across the industry, with potential enforcement around GLP-1 APIs FDA is moving to restrict

The ongoing SOUL trial is examining cardiovascular outcomes among patients being treated with oral semaglutide vs placebo with the primary outcome of time from randomization to the first occurrence of a major adverse CV event

1 2 At AgelessRx, GLP-1 plans are available in both full-dose and Microdosing options, which broadens the range of individuals who may benefit beyond those seeking significant weight loss alone

Members of the AK1C family, belonging to AKRs superfamily, have been suggested to play a pivotal role in maintaining steroid homeostasis 29

However, severe or persistent reflux lasting more than 2 weeks, accompanied by difficulty swallowing or chest pain, warrants immediate communication with your PlexusDx provider to rule out other conditions and adjust your dosing schedule if necessary